𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Southwest oncology group strategies in prostatic carcinoma

✍ Scribed by E. David Crawford; Maha Hussain; Edward P. Deantoni; Ian M. Thompson; Mario A. Eisenberger; Brent Blumenstein; Charles A. Coltman Jr.

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
543 KB
Volume
11
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

✦ Synopsis

The Southwest Oncology Group Genitourinary Committee evolved in 1978 from a combined gynecologic-urologic cancer committee. A significant catalyst in this development was the growing interest in prostatic carcinoma, with an initial focus on hormone refractory disease. Clinical studies have expanded into combined androgen blockade, untreated metastatic disease and localized prostate cancer. Since 1978, more than forty trials in prostatic carcinoma have been conducted. Currently, seven are in progress or under development. Conclusions and future directions are reviewed.

πŸ“œ SIMILAR VOLUMES

VM-26 in colorectal carcinoma: A Southwe
VM-26 in colorectal carcinoma: A Southwest Oncology Group study
✍ Noboru Oishi; Thomas R. Fleming; Leslie Laufman; James S. Ungerleider; Ronald B. πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 166 KB

In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observ

Southwest Oncology Group studies in blad
Southwest Oncology Group studies in bladder cancer
✍ E. David Crawford; David P. Wood; Daniel P. Petrylak; Jennifer Scott; Charles A. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

Over 50,000 patients are diagnosed annually with bladder cancer, and approximately 10,000 eventually will die of their disease. Thus, the Southwest Oncology Group (SWOG) Genitourinary Cancer Committee is committed to the study of therapeutic interventions in patients with superficial, invasive, and

Antiandrogen withdrawal in castrate-refr
Antiandrogen withdrawal in castrate-refractory prostate cancer : A Southwest Oncology Group trial (SWOG 9426)
✍ A. Oliver Sartor; Catherine M. Tangen; Maha H. A. Hussain; Mario A. Eisenberger; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 143 KB

## Abstract ## BACKGROUND. Antiandrogen withdrawal is a potential therapeutic maneuver for patients with progressive prostate cancer. This study was designed to examine antiandrogen withdrawal effects within the context of a large multi‐institutional prospective trial. ## METHODS. Eligibility cr

Phase II evaluation of mitoxantrone in a
Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study
✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

Evaluation of multimodality treatment of
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060
✍ Elizabeth A. Poplin; Joth Jacobson; Arnold Herskovic; Timothy J. Panella; Manuel πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 598 KB

## BACKGROUND. Continuous infusion 5-fluorouracil (CI5-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination